Nasdaq Grants CytoSorbents 180-Day Extension to Regain Minimum Bid Price Compliance

summarizeSummary

CytoSorbents received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule, with a new deadline of September 28, 2026, and is considering a reverse stock split.

check_boxKey Events

• Nasdaq Grants Compliance Extension

  CytoSorbents Corporation received a 180-day extension from Nasdaq, until September 28, 2026, to regain compliance with the $1.00 minimum bid price requirement.

• Ongoing Listing Challenge

  This extension follows an initial notice received on October 2, 2025, highlighting the company's persistent challenge in maintaining its Nasdaq listing.

• Reverse Stock Split Under Consideration

  The company is actively monitoring its stock price and considering options, including a reverse stock split, to resolve the deficiency.

• No Immediate Delisting

  The extension has no immediate effect on the listing of the Common Stock on Nasdaq.

auto_awesomeAnalysis

This 8-K details that CytoSorbents has received a 180-day extension from Nasdaq to meet the $1.00 minimum bid price requirement, pushing the deadline to September 28, 2026. While this avoids immediate delisting, it underscores the company's ongoing struggle with its stock price, which is currently well below the threshold. The company's consideration of a reverse stock split, if necessary, is a common but often negatively perceived measure to address such compliance issues. This development adds to the concerns raised by the recent 10-K, which included a going concern warning and material weaknesses in financial controls. Investors should monitor the company's progress in regaining compliance and any potential announcements regarding a reverse stock split, as failure to comply could lead to delisting.